Scaffold proteins promote the formation of stable complexes, which subsequently enhance LLPS.[18, 42] Aberrant phase separation of KAT6A, assisted by APEX1, regulates the subcellular distribution of PARP1 and decreases PARP1 trapping‐mediated cytotoxic effects of PARPi treatment, leading to resistance to PARPi in ovarian cancer cells. Here, KAT6A is linked to ovarian carcinoma.